NASDAQ:EWTX Edgewise Therapeutics (EWTX) Stock Price, News & Analysis $31.43 -0.29 (-0.91%) Closing price 04:00 PM EasternExtended Trading$31.42 0.00 (-0.02%) As of 06:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Edgewise Therapeutics Stock (NASDAQ:EWTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Edgewise Therapeutics alerts:Sign Up Key Stats Today's Range$31.02▼$32.0950-Day Range$28.66▼$38.0152-Week Range$12.15▼$39.96Volume1.06 million shsAverage Volume1.39 million shsMarket Capitalization$3.38 billionP/E RatioN/ADividend YieldN/APrice Target$39.67Consensus RatingModerate Buy Company Overview Edgewise Therapeutics, Inc. (NASDAQ: EWTX) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the discovery and development of precision medicines for the treatment of rare diseases. The company leverages its expertise in small-molecule chemistry and ion channel biology to address severe, unmet medical needs, particularly in the areas of kidney disorders and neuromuscular diseases. At the core of Edgewise’s pipeline is EWTX-101, a novel, orally available inhibitor of TRPC5, a calcium channel implicated in nephrotic syndromes such as focal segmental glomerulosclerosis (FSGS) and other proteinuric kidney diseases. By targeting the underlying mechanisms of podocyte injury, EWTX-101 is designed to reduce proteinuria and preserve renal function. The company also has earlier-stage programs exploring additional ion channel and intracellular targets, with the aim of expanding its portfolio into other rare diseases driven by calcium dysregulation. Founded in 2018 by a team of drug development and neuroscience specialists, Edgewise completed its initial public offering in mid-2020. The company’s leadership comprises industry veterans with extensive experience in clinical translation, regulatory strategy and commercial planning. Edgewise operates primarily in the United States but is preparing for global clinical trials, seeking to establish collaborations and partnerships to facilitate broader patient access. Looking ahead, Edgewise Therapeutics is advancing its lead asset through multiple clinical studies while progressing preclinical candidates toward IND filing. By combining deep scientific insight with a nimble development approach, the company aims to bring innovative therapies to patients who currently have limited or no treatment options.AI Generated. May Contain Errors. Read More Edgewise Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreEWTX MarketRank™: Edgewise Therapeutics scored higher than 50% of companies evaluated by MarketBeat, and ranked 537th out of 851 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingEdgewise Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 2 strong buy ratings, 5 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialEdgewise Therapeutics has a consensus price target of $39.67, representing about 26.2% upside from its current price of $31.43.Amount of Analyst CoverageEdgewise Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Edgewise Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Edgewise Therapeutics are expected to decrease in the coming year, from ($2.13) to ($2.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Edgewise Therapeutics is -18.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Edgewise Therapeutics is -18.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEdgewise Therapeutics has a P/B Ratio of 6.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Edgewise Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.26% of the float of Edgewise Therapeutics has been sold short.Short Interest Ratio / Days to CoverEdgewise Therapeutics has a short interest ratio ("days to cover") of 9.34.Change versus previous monthShort interest in Edgewise Therapeutics has recently increased by 0.57%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEdgewise Therapeutics does not currently pay a dividend.Dividend GrowthEdgewise Therapeutics does not have a long track record of dividend growth. News and Social Media2.1 / 5News SentimentN/A News SentimentEdgewise Therapeutics has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.Search Interest3 people have searched for EWTX on MarketBeat in the last 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Edgewise Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,018,216.00 in company stock.Percentage Held by Insiders23.20% of the stock of Edgewise Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsEdgewise Therapeutics has minimal institutional ownership at this time.Read more about Edgewise Therapeutics' insider trading history. Receive EWTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Edgewise Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EWTX Stock News HeadlinesEdgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2026May 12, 2026 | prnewswire.comGuggenheim Reaffirms Their Buy Rating on Edgewise Therapeutics (EWTX)May 12, 2026 | theglobeandmail.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.May 19 at 1:00 AM | InvestorPlace (Ad)Edgewise Therapeutics (EWTX) Receives a Buy from WedbushMay 12, 2026 | theglobeandmail.comEdgewise Therapeutics Reports First Quarter 2026 Financial Results and Advances Clinical Programs in Muscular Dystrophy and Cardiovascular IndicationsMay 7, 2026 | prnewswire.comJoanne Donovan Sells 5,230 Shares of Edgewise Therapeutics (NASDAQ:EWTX) StockMay 6, 2026 | insidertrades.comCYTK stock jumped to over 2-year highs on HCM trial outcome – so, why are analysts bullish on Edgewise Therapeutics?May 5, 2026 | msn.comEdgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing RulesMay 4, 2026 | prnewswire.comSee More Headlines EWTX Stock Analysis - Frequently Asked Questions How have EWTX shares performed this year? Edgewise Therapeutics' stock was trading at $24.82 at the start of the year. Since then, EWTX shares have increased by 26.6% and is now trading at $31.43. How were Edgewise Therapeutics' earnings last quarter? Edgewise Therapeutics, Inc. (NASDAQ:EWTX) posted its quarterly earnings data on Thursday, May, 7th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.50) by $0.04. When did Edgewise Therapeutics IPO? Edgewise Therapeutics (EWTX) raised $165 million in an initial public offering on Friday, March 26th 2021. The company issued 11,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs, SVB Leerink and Wedbush PacGrow served as the underwriters for the IPO. Who are Edgewise Therapeutics' major shareholders? Edgewise Therapeutics' top institutional investors include Janus Henderson Group PLC (5.50%), Siren L.L.C. (4.12%), Bank of America Corp DE (1.23%) and Dimensional Fund Advisors LP (1.13%). Insiders that own company stock include Orbimed Advisors Llc, Peter A Thompson, R Michael Carruthers, Kevin Koch, Jonathan C Fox, Alan J Russell, Badreddin Edris, Behrad Derakhshan, John R Moore, Marc Semigran and Joanne M Donovan. View institutional ownership trends. How do I buy shares of Edgewise Therapeutics? Shares of EWTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Edgewise Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Edgewise Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Tesla (TSLA), JPMorgan Chase & Co. (JPM) and First Solar (FSLR). Company Calendar Last Earnings5/07/2026Today5/19/2026RBC Capital Markets Global Healthcare Conference 20265/20/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (6m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 EWTX's financial health is in the Green zone, according to TradeSmith. EWTX has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:EWTX CIK1710072 Webwww.edgewisetx.com Phone720-262-7002FaxN/AEmployees60Year Founded1962Price Target and Rating Average Price Target for Edgewise Therapeutics$39.67 High Price Target$52.00 Low Price Target$20.00 Potential Upside/Downside+26.2%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($1.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$167.79 million Net MarginsN/A Pretax MarginN/A Return on Equity-32.55% Return on Assets-31.04% Debt Debt-to-Equity RatioN/A Current Ratio22.61 Quick Ratio22.61 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.58 per share Price / Book6.86Miscellaneous Outstanding Shares107,590,000Free Float82,631,000Market Cap$3.38 billion OptionableOptionable Beta0.25 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free Report This page (NASDAQ:EWTX) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe AI stocks about to become worthless (and one that isn't)Louis Navellier - who manages $1.1 billion including $358 million in AI stocks - says a new AI computer being ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edgewise Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Edgewise Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
